Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Biomea Fusion Inc. is managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners and 3 distinct art units. WHITE, DAWANNA SHAR-DAY is the busiest examiner with 1 pending office action, indicating that each pending matter is being reviewed by a different individual. This distribution suggests a lack of examiner concentration, which may lead to varied prosecution experiences across the portfolio.
The 3 distinct art units involved indicate that while the portfolio is centered on Biotechnology & Pharmaceuticals, it touches upon different technical niches. For a practitioner, this means that there is no single examiner whose historical data will dominate the outcome of the current docket. The presence of 4 distinct examiners requires a flexible prosecution strategy that can adapt to the different standards and practices of these various individuals.
With 4 pending office actions and 3 distinct art units, the company's innovations are being reviewed by multiple specialized groups within the USPTO. This breadth suggests that the biotechnology focus covers several sub-specialties. The 4 distinct examiners ensure that the 4 pending office actions are each given an independent look, reducing the risk that a single examiner's bias could affect a large portion of the company's active applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| TRAN, ERIC | 1 | 69.8% | +19.4% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| ROMERO, KRISTEN WANG | 1 | 69.8% | +30.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18768954 | N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOF | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18871252 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | WHITE, DAWANNA SHAR-DAY | — |
| 18926210 | COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUS | TRAN, ERIC | — |
| 18768954 | N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOF | WILLIS, DOUGLAS M | — |
| 18257541 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | ROMERO, KRISTEN WANG | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1627 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18871252 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | WHITE, DAWANNA SHAR-DAY | 1627 | §103§112DP | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18926210 | COVALENT INHIBITORS OF MENIN-MLL INTERACTION FOR DIABETES MELLITUS | TRAN, ERIC | 1629 | §112DP | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18768954 | N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOF | WILLIS, DOUGLAS M | 1624 | DP | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18257541 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | ROMERO, KRISTEN WANG | 1624 | §112DP | Final Rejection | — | Pending | Jun 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiomea Fusion Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Dawanna Shar-Day White has the most, with 1 of Biomea Fusion Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
